Kaulanjan, K.; Dahan, J.; Charrois-Durand, C.; Saad, F.; Brureau, L.; Delouya, G.; Taussky, D.; Auclin, E.
Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride. Cancers 2022, 14, 4606.
https://doi.org/10.3390/cancers14194606
AMA Style
Kaulanjan K, Dahan J, Charrois-Durand C, Saad F, Brureau L, Delouya G, Taussky D, Auclin E.
Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride. Cancers. 2022; 14(19):4606.
https://doi.org/10.3390/cancers14194606
Chicago/Turabian Style
Kaulanjan, Kevin, Johanna Dahan, Cédric Charrois-Durand, Fred Saad, Laurent Brureau, Guila Delouya, Daniel Taussky, and Edouard Auclin.
2022. "Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride" Cancers 14, no. 19: 4606.
https://doi.org/10.3390/cancers14194606
APA Style
Kaulanjan, K., Dahan, J., Charrois-Durand, C., Saad, F., Brureau, L., Delouya, G., Taussky, D., & Auclin, E.
(2022). Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride. Cancers, 14(19), 4606.
https://doi.org/10.3390/cancers14194606